Retrophin to Report Third Quarter 2020 Financial Results
21 oct. 2020 16h30 HE
|
Retrophin, Inc.
SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report third quarter 2020 financial results on Thursday, November 5, 2020 after the close of the...
Retrophin to Present at Upcoming Investor Conferences
03 août 2020 16h30 HE
|
Retrophin, Inc.
SAN DIEGO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will participate in the following upcoming virtual investor conferences in August:...
Retrophin to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
19 juin 2020 08h00 HE
|
Retrophin, Inc.
SAN DIEGO, June 19, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the BMO 2020 Prescriptions for Success...
Retrophin Reports Fourth Quarter and Full Year 2019 Financial Results
24 févr. 2020 16h01 HE
|
Retrophin, Inc.
Pivotal DUPLEX and PROTECT studies of sparsentan enrolling towards topline readouts to support potential NDA and CMA filings Full year 2019 net product sales of $175 million SAN DIEGO, Feb. 24,...
Retrophin Announces Topline Results from Phase 3 FORT Study of Fosmetpantotenate in Patients with PKAN
22 août 2019 06h00 HE
|
Retrophin, Inc.
FORT Study did not achieve its primary or secondary endpoints Company to host conference call and webcast today at 8:30 a.m. ET SAN DIEGO, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc....
Retrophin to Present at Canaccord Genuity’s 39th Annual Growth Conference
31 juil. 2019 16h30 HE
|
Retrophin, Inc.
SAN DIEGO, July 31, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the Canaccord Genuity 39th Annual Growth...
Retrophin to Report Second Quarter 2019 Financial Results
23 juil. 2019 16h30 HE
|
Retrophin, Inc.
SAN DIEGO, July 23, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report second quarter 2019 financial results on Tuesday, August 6, 2019 after the close of the...
Retrophin Announces FDA Approval of THIOLA® EC (tiopronin) 100mg and 300mg Tablets for the Treatment of Cystinuria
28 juin 2019 16h34 HE
|
Retrophin, Inc.
Enteric-coated formulation offers flexible dosing options, including administration with or without food THIOLA EC expected to be available to patients next month SAN DIEGO, June 28, 2019 (GLOBE...
Retrophin Announces Cooperative Research and Development Agreement with NCATS and the Alagille Syndrome Alliance to Identify Potential Therapeutics for Alagille Syndrome
18 juin 2019 16h30 HE
|
Retrophin, Inc.
SAN DIEGO, June 18, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it has entered into a three-way Cooperative Research and Development Agreement (CRADA) with the...
Retrophin to Present at Upcoming Investor Conferences
30 mai 2019 16h30 HE
|
Retrophin, Inc.
SAN DIEGO, May 30, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will present at the following upcoming investor conferences in June: Jefferies...